August 10, 2009
Sepracor Seeks Canadian Approval For Epilepsy Drug
By Matthew L. Brown
Marlborough-based Sepracor Inc. has asked the Canadian government to approve a new treatment for epileptic seizures.
The company submitted its application to the Therapeutic Products Directorate of Health Canada through a Canadian subsidiary called Sepracor Pharmaceuticals Inc. Sepracor Pharmaceuticals was formed when the company acquired Oryx Pharmaceuticals last year. The new application is the company's first submitted in Canada.
The new drug is called Stedesa. The company has applied for approval from the U.S. Food and Drug Administration and expects the FDA to take action next year.
Stedesa is designed to reduce the frequency of certain seizures in epileptic adults.
WBJ Web Partners
Most Recent
Most Recent
0 Comments